A better clot-buster drug for strokes?

April 26, 2018 by Steven Reinberg, Healthday Reporter

(HealthDay)—After a stroke, many patients are given the clot-busting intravenous drug alteplase, but another drug may be more effective, Australian researchers report.

Among more than 200 , TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.

"Tenecteplase is likely to become the preferred medication for clot-dissolving in stroke patients," said lead researcher Dr. Bruce Campbell, head of the stroke department at the Royal Melbourne Hospital in Parkville. "It is likely to change stroke treatment guidelines and clinical practice."

Campbell said tenecteplase is more effective than alteplase because of differences in the enzymes in each .

Although both drugs work in the same way, tenecteplase is better at attacking and dissolving clots, and more resistant to factors that inhibit the breakdown of clots, he said.

For either drug to be most effective, it needs to be given as soon as possible after a stroke occurs. In this study, patients were given the drugs within 4.5 hours after the onset of a stroke, Campbell said.

Although tenecteplase appears to be more effective for stroke patients, it's not approved for that use in the United States, according to Dr. Rohan Arora, director of at Long Island Jewish Hospital in Forest Hills, N.Y.

In 2000, the U.S. Food and Drug Administration approved tenecteplase for use after a , Arora said.

"Tenecteplase is being widely used in developing countries, such as India," he said. "One reason is it's cheaper than alteplase."

In the United States, tenecteplase costs about $5,800, versus alteplase, which costs $8,000, Arora said.

In addition, tenecteplase is easier to give, requiring only a single injection, while alteplase requires an injection and an IV drip, he added.

Arora explained that tenecteplase is not widely used in the United States for because these patients are typically treated with angioplasty or heart bypass surgery.

For the new study, which did not receive drug company funding, Campbell and his colleagues randomly assigned 202 to either alteplase or tenecteplase before surgery to remove clots.

The researchers specifically looked to see which drug was better at restoring blood flow to clot-blocked blood vessels in the brain, and which drug resulted in patients having better outcomes.

The investigators found that 22 percent of the patients treated with tenecteplase had more than 50 percent of return to the brain, compared with 10 percent of those treated with alteplase.

Patients treated with tenecteplase also had better functional outcomes after 90 days than those given alteplase, the findings showed.

Bleeding into the brain, the most serious side effect of either drug, occurred in 1 percent of , regardless of which drug they received, Campbell said.

The report was published April 26 in the New England Journal of Medicine.

Explore further: New drug treatment could offer stroke survivors better outcomes

More information: Bruce Campbell, MBBS, Ph.D., head, stroke department, Royal Melbourne Hospital, Parkville, Australia; Rohan Arora, MBBS, director, stroke, Long Island Jewish Hospital, Forest Hills, New York; April 26, 2018, New England Journal of Medicine.

For more on stroke, visit the National Stroke Association.

Related Stories

New drug treatment could offer stroke survivors better outcomes

February 26, 2015
Promising results for a new drug treatment for ischaemic stroke patients have been published today in the journal Lancet Neurology.

Tenecteplase drug bests standard treatment for certain strokes

March 22, 2012
(HealthDay) -- A medication called tenecteplase may be more effective at treating strokes caused by clots in large blood vessels in the brain than the current standard therapy, Australian researchers report.

Ischemic stroke patients not receiving life-saving treatment, study finds

October 5, 2017
Ischemic stroke patients who do not receive intravelous (IV) alteplase, a clot-dissolving medication, are significantly less likely to survive, according to researchers at Georgia State University.

Benefits / risks for fibrinolytic therapy in intermediate-risk PE

April 11, 2014
(HealthDay)—A single intravenous bolus of tenecteplase reduces early death and hemodynamic decompensation in normotensive patients with intermediate-risk pulmonary embolism, but increases the risk of major hemorrhage and ...

Low-dose alteplase no better for acute ischemic stroke

October 3, 2017
(HealthDay)—For key demographic subgroups of patients with acute ischemic stroke (AIS), low-dose alteplase does not differ from standard-dose alteplase in terms of treatment effects on death or disability, according to ...

Brain scan study shows clot-busting drug benefits stroke patients

April 9, 2015
A drug that breaks up blood clots in the brains of stroke patients could be used more widely than at present without increased risk, a brain scan study suggests.

Recommended for you

New cellular pathway helps explain how inflammation leads to artery disease

June 21, 2018
Investigators have identified a new cellular pathway that may help explain how arterial inflammation develops into atherosclerosis—deposits of cholesterol, fats and other substances that create plaque, clog arteries and ...

'Smart stent' detects narrowing of arteries

June 19, 2018
For every three individuals who have had a stent implanted to keep clogged arteries open and prevent a heart attack, at least one will experience restenosis—the renewed narrowing of the artery due to plaque buildup or scarring—which ...

Marriage may protect against heart disease / stroke and associated risk of death

June 18, 2018
Marriage may protect against the development of heart disease/stroke as well as influencing who is more likely to die of it, suggests a pooled analysis of the available data, published online in the journal Heart.

Deaths from cardiac arrest are misclassified, overestimated

June 18, 2018
Forty percent of deaths attributed to cardiac arrest are not sudden or unexpected, and nearly half of the remainder are not arrhythmic—the only situation in which CPR and defibrillators are effective—according to an analysis ...

Tick-borne meat sensitivity linked to heart disease

June 15, 2018
University of Virginia School of Medicine researchers have linked sensitivity to an allergen in red meat—a sensitivity spread by tick bites—with a buildup of fatty plaque in the arteries of the heart. This buildup may ...

Tobacco aside, e-cigarette flavorings may harm blood vessels

June 14, 2018
Flavor additives used in electronic cigarettes and related tobacco products could impair blood vessel function and may be an early indicator of heart damage, according to new laboratory research in Arteriosclerosis, Thrombosis ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.